Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.52 |
| ▸ | MTOR | P42345 | 16/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.51 |
| ▸ | PRKDC | P78527 | 3/20 | 0.51 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.51 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | ATR | Q13535 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.51 |
| ▸ | LTK | P29376 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | NEK2 | P51955 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1073153 | 0.94 | PIK3CA (0.54) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1073147 | 0.93 | PIK3CA (0.55) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1074229 | 0.93 | PIK3CA (0.52) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1072887 | 0.92 | PIK3CA (0.58) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1073856 | 0.91 | PIK3CA (0.52) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1074199 | 0.91 | PIK3CA (0.52) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1073968 | 0.91 | PIK3CA (0.51) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1073234 | 0.90 | PIK3CA (0.52) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1074292 | 0.90 | PIK3CA (0.50) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1074302 | 0.87 | PIK3CA (0.49) | PIK3CAMTORPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637670-B2 | Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation | Piramal Enterprises Limited (IN) | 2014-01-28 | — | — | US | claimed |
| EP-2448937-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Life Sciences Limited (IN) | 2012-05-09 | — | — | EP | claimed |
| US-20120108627-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Enterprises Limited (IN) | 2012-05-03 | — | — | US | claimed |
| WO-2011001212-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-01-06 | — | — | WO | claimed |
| US-8637670-B2 | Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation | Piramal Enterprises Limited (IN) | 2014-01-28 | — | — | US | disclosed |
| EP-2448937-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Life Sciences Limited (IN) | 2012-05-09 | — | — | EP | disclosed |
| US-20120108627-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Enterprises Limited (IN) | 2012-05-03 | — | — | US | disclosed |
| WO-2011001212-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108627-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | IL6, RPS6KA6, MTOR | PIK3CA 91/4885MTOR 3/4885PIK3CD 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.